A surprising new analysis suggests that semaglutide — the active ingredient in Ozempic and Wegovy — may do more than manage diabetes and aid weight loss. It could also cut the risk of serious asthma attacks by nearly 40%.
The findings, published in the journal JAMA Internal Medicine, come from an analysis of electronic health records covering more than 7,000 adults with asthma who were new users of GLP-1 medications. The researchers compared people taking semaglutide against those using other classes of weight-loss or diabetes drugs, tracking them for an average of about six months.
Those prescribed semaglutide had a 38% to 40% lower rate of asthma exacerbations — events where patients needed oral steroids, emergency care, or hospitalization — compared with similar patients on non-GLP-1 medications. The result held even when the researchers adjusted for body mass index change, suggesting the effect is not simply a byproduct of weight loss.
The study's lead author, Dr. Cian P. McCarthy of Massachusetts General Hospital, told reporters the findings point to a possible anti-inflammatory effect of GLP-1 drugs in the airways. "We were not expecting this magnitude of reduction, especially independent of weight loss," he said.
Strengths of the study include its large sample size and real-world design, but the authors acknowledge limits: the data is observational, so it cannot prove cause and effect. The study also did not break down results by patient sex, and most participants were female.
The findings arrive amid growing interest in whether drugs like Ozempic can treat conditions beyond obesity and diabetes. Earlier research has hinted at cardiovascular benefits, and separate trials are now examining GLP-1 drugs for conditions like sleep apnea, kidney disease, and even addiction. The new asthma data adds the lungs to that expanding list.
Researchers say the next step is clinical trials designed specifically to test semaglutide in people with asthma and COPD. If confirmed, the drug could become an unexpected new option for millions of Americans managing airway disease.